Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Rapamycin Nanoparticles Correct Autophagy Defects in Mouse Muscular Dystrophy Model

By BiotechDaily International staff writers
Posted on 25 Feb 2014
Print article
Image: The mouse in the upper right is the mutant mdx/mdx and is shown with a normal control (Photo courtesy of the Jackson Laboratory).
Image: The mouse in the upper right is the mutant mdx/mdx and is shown with a normal control (Photo courtesy of the Jackson Laboratory).
Nanoparticles coated with rapamycin were found to improve strength and heart function in a mouse model for Duchenne muscular dystrophy.

Duchenne muscular dystrophy in boys progresses rapidly to severe impairment of muscle function and death in the second or third decade of life. Current supportive therapy with corticosteroids results in a modest increase in strength as a consequence of a general reduction in inflammation, but with potential untoward long-term side effects and ultimate failure of the agent to maintain strength.

The primary molecular factor responsible for Duchenne muscular dystrophy is a mutation that prevents the body from producing dystrophin, a protein crucial for maintaining muscle cell integrity and function. In addition, studies with the mdx mouse model of Duchenne muscular dystrophy have shown that defective autophagy is involved in the pathology of the disease.

Investigators at Washington University School of Medicine (St. Louis, MO, USA) looked for ways to correct the autophagy defects. To this end, they developed a class of perfluorocarbon nanoparticles coated with the drug rapamycin. Rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. The drug prevents activation of T-cells and B-cells by inhibiting their response to interleukin-2 (IL-2). It is also used as a coronary stent coating. Rapamycin works, in part, by eliminating old and abnormal white blood cells and is effective in mice with autoimmunity and in children with the rare condition autoimmune lymphoproliferative syndrome (ALPS).

The investigators reported in the February 5, 2014, online edition of the FASEB Journal that following injection, the nanoparticles collected at sites of inflammation, allowing the drug to penetrate muscle tissue. Treated mice showed a 30% increase in grip strength and a significant improvement in cardiac function, based on an increase in the volume of blood the heart pumped. This increase in physical performance occurred in both young and adult mdx mice, and even in aged wild-type mice, which sets the stage for consideration of systemic therapies to facilitate improved cell function by autophagic disposal of toxic byproducts of cell death and regeneration.

“Autophagy plays a major role in disposing of cellular debris,” said senior author Dr. Samuel A. Wickline, professor of medicine at Washington University School of Medicine. “If it does not happen, you might say the cell chokes on its own refuse. In muscular dystrophy, defective autophagy is not necessarily a primary source of muscle weakness, but it clearly becomes a problem over time. If you solve that, you can help the situation by maintaining more normal cellular function.”

“An important aspect of our study is that we are treating both skeletal muscle and heart muscle with the same drug,” said Dr. Wickline. “The heart is a difficult organ to treat in muscular dystrophy. But even in older animals, this regimen works well to recover heart function, and it is effective over a short period of time and after only a few doses.”

Related Links:

Washington University School of Medicine



Print article

Channels

Genomics/Proteomics

view channel
Image: A dark field photomicrograph showing the spirochete bacterium Borrelia burgdorferi, the pathogen responsible for causing Lyme disease (Photo courtesy of the CDC).

Statins May Help Block Transmission of Lyme Disease

A recent study found that treatment with cholesterol-lowering statins reduced the number of Borrelia burgdorferi bacteria in rodents, which helped to block transmission of Lyme disease. Lyme disease... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.